Skip to main content

Ongoing launch of Emtrix® in Canada by Paladin Labs

The largest drugstore chain in Canada has made their first orders

In December 2012 Moberg Pharma signed an exclusive distribution agreement for Canada with Paladin Labs for Nalox™/Emtrix®, a novel, over-the-counter product for the local treatment of fingernail and toenail fungal infections. Paladin Labs, one of the largest pharmaceutical companies in Canada, reported in August the launch of the product on the Canadian market., which will be sold under the brand name Emtrix®.

The initial focus will be on the larger drugstore chains and Emtrix® is already available in close to 50 per cent of the drugstores at Shoppers Drug Mart, the largest drugstore chain in Canada. In addition, Paladin has achieved listing of Emtrix® in a majority of the drugstore retailers in Canada. Launch in these drugstore chains will follow during the autumn and spring of 2013/2014.

About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 35 countries. The company’s product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Kerasal Nail®and Kaprolac®. Kerasal Nail®(Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: